Skip to main
ALKS

Alkermes (ALKS) Stock Forecast & Price Target

Alkermes (ALKS) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 13%
Sell 7%
Strong Sell 0%

Bulls say

Alkermes is in a strong position with a diverse pipeline, a track record of successful partnerships, and a focus on unmet medical needs. Their financials show positive growth with solid revenues and a net income of $83.8 million in the first quarter of 2021. Additionally, the company's strategic partnerships and collaborations provide access to resources and expertise that can support the development and commercialization of their products. These factors, combined with the potential for their orexin portfolio and other products, make Alkermes a favorable investment opportunity with strong potential for growth in the biotechnology industry.

Bears say

Alkermes is positioned well for long-term growth in the biotechnology sector with its proprietary technologies and established partnerships. However, the limited efficacy of their orexin drugs in addressing the core symptoms of IH and ADHD, and competition from other approved treatments may limit its potential. Additionally, the small sample sizes in studies may not fully support the efficacy of their drugs, and their position as a second-to-market may pose challenges in gaining market share.

Alkermes (ALKS) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 13% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alkermes (ALKS) Forecast

Analysts have given Alkermes (ALKS) a Buy based on their latest research and market trends.

According to 15 analysts, Alkermes (ALKS) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alkermes (ALKS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.